TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22515800

Group type: EXPERIMENTAL
Intervention: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections at 1, 5, and 9 weeks, with as-needed treatments at weeks 13 and 17.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 15% dextrose extra-articular injections and 25% dextrose intra-articular prolotherapy injections.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-dose opioid analgesia for procedure-related pain.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy.
Number of subjects: 36
Study: 22516251

Group type: EXPERIMENTAL
Intervention: Paliperidone extended release (ER)
Number of subjects: 291
Study: 22516395

Group type: EXPERIMENTAL
Intervention: New crossing catheter and re-entry system
Number of subjects: 147
Study: 22516397

Group type: EXPERIMENTAL
Intervention: FFR measurement in MV ostial lesions
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: FFR measurement in SB ostial lesions
Number of subjects: 93
Study: 22516401

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 28
Study: 22516441

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 0
Study: 22517196

Group type: EXPERIMENTAL
Intervention: Paper version of ICIQ-LUTSqol (n=78)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Web-based version of ICIQ-LUTSqol (n=54)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both paper and web-based versions
Number of subjects: 132
Study: 22517904

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d (RdC)
Number of subjects: 37
Study: 22518187

Group type: EXPERIMENTAL
Intervention: Antenatal music exposure (listening to a pre-recorded music cassette for approximately 1 hour/day in addition to standard antenatal care)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard care only (control arm)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Antenatal music exposure
Number of subjects: 260
Study: 22520270

Group type: EXPERIMENTAL
Intervention: TNFerade biologic (5 weekly injections, dose-escalated from 4 × 10(8) to 4 × 10(11) PU) combined with chemoradiotherapy (cisplatin 75 mg/m(2), 5-fluorouracil 1000 mg/m(2)/d for 96 hours, radiation therapy to 45 Gy)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TNFerade biologic with chemoradiotherapy
Number of subjects: 24
Study: 22520529

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound analysis of plaque distribution in LAD
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound analysis of plaque distribution in RCA
Number of subjects: 136
Study: 22520686

Group type: EXPERIMENTAL
Intervention: FCH PET/CT
Number of subjects: 210
Study: 22520945

Group type: EXPERIMENTAL
Intervention: Oseltamivir (30-75 mg once daily for 6 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pooled safety data from treatment studies (duration of 5 days) in children
Number of subjects: 49
Study: 22522212

Group type: EXPERIMENTAL
Intervention: WNT2 gene SNP rs2896218
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Three-locus haplotype in the WNT2 gene
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Interaction effect between SNP rs2228946 in WNT2 and SNP rs6460013 in EN2
Number of subjects: 373
Study: 22522612

Group type: EXPERIMENTAL
Intervention: Naloxone infusion during exercise (N+)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Saline infusion during exercise (N-)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Naloxone infusion without exercise (control)
Number of subjects: 8
Study: 22522617

Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xenin-25
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GIP plus Xenin-25
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 0
Study: 22523054

Group type: EXPERIMENTAL
Intervention: In-hospital events; cardiovascular events, hospital admissions and mortality during follow-up.
Number of subjects: 4169
Study: 22523260

Group type: EXPERIMENTAL
Intervention: Doxycycline for 15 days
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Doxycycline for 10 days
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Patients with erythema migrans
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control subjects without a history of Lyme borreliosis
Number of subjects: 117
Study: 22523360

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) during noninvasive ventilation (NIV) without leaks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) during noninvasive ventilation (NIV) with induced leaks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) compared to oesophageal pressure (P(oes))
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pulse transit time (PTT) during nocturnal NIV in OHS patients
Number of subjects: 21
Study: 22523363

Group type: EXPERIMENTAL
Intervention: Severe obstructive sleep apnoea/hypopnoea (OSAH) defined by an apnoea/hypopnoea index (AHI) >30 · h(-1) (17% of subjects)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Moderate OSAH (AHI 15-30)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Severe OSAH
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: SRBD severity expressed using ODI >10 · h(-1)
Number of subjects: 470
Study: 22524591

Group type: EXPERIMENTAL
Intervention: TExT-MED program (text message-based intervention, 3 messages daily for 3 weeks)
Number of subjects: 23
Study: 22524974

Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Number of subjects: 14
Study: 22525392

Group type: EXPERIMENTAL
Intervention: Alkali-treated penicillin G
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Penicillin G sodium (PGs)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Commercial reagents (PPL + DAP-MDM)
Number of subjects: 68
Study: 22525883

Group type: EXPERIMENTAL
Intervention: certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks up to week 52
Number of subjects: 89
Study: 22526363

Group type: EXPERIMENTAL
Intervention: Cy-Flu-ATG
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cy-ATG
Number of subjects: 83
Study: 22527084

Group type: EXPERIMENTAL
Intervention: Standardised drug labelling used hospital-wide
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Standardised drug labelling used in ICU
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Standardised drug labelling by region
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Use of ISO 26825 norm
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Desire for ISO 26825 norm labelling from pharmaceutical industry
Number of subjects: 482
Study: 22527314

Group type: EXPERIMENTAL
Intervention: FUSION regimen (ranibizumab)
Number of subjects: 17
Study: 22528284

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DARB) 1 mg/kg IV immediately before surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DARB)
Number of subjects: 18
Study: 22529239

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22529273

Group type: EXPERIMENTAL
Intervention: Standard perioperative care with intraoperative morphine
Number of subjects: 194
Study: 22529995

Group type: EXPERIMENTAL
Intervention: 3T MRI FLAIR images in ALS patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 7T MRI T(2)(*)-weighted gradient echo imaging
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pathological studies
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3T MRI FLAIR images
Number of subjects: 38
Study: 22531596

Group type: EXPERIMENTAL
Intervention: ABSORB scaffold implantation
Number of subjects: 83
Study: 22531869

Group type: EXPERIMENTAL
Intervention: Single complete compression ultrasonography
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Negative single complete compression ultrasonography result
Number of subjects: 210
Study: 22533698

Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV) or ganciclovir (GCV) prophylaxis (n = 20)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No chemoprophylaxis (n = 8)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV) or ganciclovir (GCV) prophylaxis
Number of subjects: 114
Study: 22534421

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass liner (DJBL)
Number of subjects: 39
Study: 22535636

Group type: EXPERIMENTAL
Intervention: In-person intervention (n=24)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Telephonic intervention (n=11)
Number of subjects: 52
Study: 22535761

Group type: EXPERIMENTAL
Intervention: Meat intake (red meat, processed meat, fish, poultry, heme iron, nitrite, nitrate, animal fat, protein)
Number of subjects: 492186

Group type: EXPERIMENTAL
Intervention: MeIQx (2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline)
Number of subjects: 492186

Group type: EXPERIMENTAL
Intervention: DiMeIQx (2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline)
Number of subjects: 492186
Study: 22536072

Group type: EXPERIMENTAL
Intervention: German physicians' attitudes towards risk factor control based on the 2007 European guidelines on cardiovascular disease prevention.
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Risk factor control rates in German patients.
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Use of risk engines by German physicians.
Number of subjects: 7641

Group type: EXPERIMENTAL
Intervention: Importance of ESC guidelines for German physicians.
Number of subjects: 7641
Study: 22536884

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin vs Placebo
Number of subjects: 0
Study: 22537054

Group type: EXPERIMENTAL
Intervention: Subjects with central obesity
Number of subjects: 595

Group type: COMPARATOR
Intervention: Subjects without central obesity
Number of subjects: 595
Study: 22537162

Group type: EXPERIMENTAL
Intervention: sunitinib + FOLFIRI
Number of subjects: 71
Study: 22537906

Group type: EXPERIMENTAL
Intervention: Molecular model for predicting bone metastasis based on CXCR4, BSP, OPN, and BMP4.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Molecular model validated in another 40 patients with stage III NSCLC.
Number of subjects: 105
Study: 22537988

Group type: EXPERIMENTAL
Intervention: 2-dose MenC vaccine (given at 2 and 4 months)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 1-dose MenC vaccine (given at 2 months)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Unvaccinated infants
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All subjects after the 12 month MenC dose
Number of subjects: 3
Study: 22539091

Group type: EXPERIMENTAL
Intervention: Tasisulam sodium (420 μg/mL) administered intravenously on day 1 of 21-day cycles
Number of subjects: 63
Study: 22539478

Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 550

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 550
Study: 22540954

Group type: EXPERIMENTAL
Intervention: 2.4 mg/kg intravenous artesunate
Number of subjects: 14
Study: 22541066

Group type: EXPERIMENTAL
Intervention: Cisplatin plus 3-AP (96 mg/m(2) for 4 days, with cisplatin at 25 mg/m(2) on days 2 and 3)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 6

Group type: COMPARATOR
Intervention: 3-AP preceding cisplatin exposure
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cisplatin plus 3-AP
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3-AP (96 mg/m(2))
Number of subjects: 6
Study: 22541178

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF) energy surgical ablation
Number of subjects: 118
Study: 22541312

Group type: EXPERIMENTAL
Intervention: Neuroprosthesis usage
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Maximum standing time
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Body weight support
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Knee strength
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Knee fatigue index
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electrode stability
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Component survivability
Number of subjects: 15
Study: 22541602

Group type: EXPERIMENTAL
Intervention: Individual HbA(1c) targets
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Physician-patient partnership
Number of subjects: 759

Group type: EXPERIMENTAL
Intervention: Expert T2D guidelines
Number of subjects: 759
Study: 22541660

Group type: EXPERIMENTAL
Intervention: Cataract surgery with intraocular lens implantation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cataract surgery with intact posterior capsules, manual posterior capsulorrhexis without anterior limbal vitrectomy, and anterior limbal vitrectomy
Number of subjects: 100
Study: 22542159

Group type: EXPERIMENTAL
Intervention: Systemic infusion of bone marrow mesenchymal stem cells (BMMSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FASL(-/-) BMMSCs
Number of subjects: 0
Study: 22542580

Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 30
Study: 22543217

Group type: EXPERIMENTAL
Intervention: Adaptive planning (replanning of radiation therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonadaptive planning (original treatment plans)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Adaptive planning
Number of subjects: 44
Study: 22543737

Group type: EXPERIMENTAL
Intervention: Post-marathon ECG parameters
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Post-marathon serum magnesium levels
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Post-marathon serum potassium levels
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Post-marathon interleukin 6 levels
Number of subjects: 198
Study: 22544699

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (rATG) and cyclosporine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Horse ATG (hATG) and cyclosporine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: rATG
Number of subjects: 35

Group type: COMPARATOR
Intervention: hATG
Number of subjects: 35
Study: 22544910

Group type: EXPERIMENTAL
Intervention: Remote follow-ups using Merlin@home and Merlin.net
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard ambulatory follow-ups
Number of subjects: 200
Study: 22545575

Group type: EXPERIMENTAL
Intervention: Storz® videolaryngoscope (SVL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Airtraq® Optical laryngoscope (AOL)
Number of subjects: 10
Study: 22545881

Group type: EXPERIMENTAL
Intervention: Ventana fenestrated stent-graft system
Number of subjects: 2
Study: 22545887

Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft with the Captivia Delivery System
Number of subjects: 100
Study: 22546242

Group type: EXPERIMENTAL
Intervention: Ezatiostat 2000 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Ezatiostat 2500 mg/day + Lenalidomide 10 mg (days 1-21 of a 28-day cycle)
Number of subjects: 19
Study: 22547151

Group type: EXPERIMENTAL
Intervention: LV-WT-HSCT
Number of subjects: 100

Group type: COMPARATOR
Intervention: WT-HSCT
Number of subjects: 100

Group type: COMPARATOR
Intervention: LV-IIIA-HSCT
Number of subjects: 100
Study: 22547163

Group type: EXPERIMENTAL
Intervention: Salirasib 200-800 mg orally (PO) twice daily (bid) for 21 days every 28 days in combination with gemcitabine.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Salirasib administered alone and in combination with gemcitabine.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Gemcitabine (standard dose schedule).
Number of subjects: 19
Study: 22547579

Group type: EXPERIMENTAL
Intervention: PBSC grafts containing dimethyl sulfoxide (DMSO) and lysed red blood cells (RBCs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBSC grafts with no DMSO and fresh RBCs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PBSC grafts with DMSO and no RBCs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 22547583

Group type: EXPERIMENTAL
Intervention: Prophylactic plasmatherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 42
Study: 22550086

Group type: EXPERIMENTAL
Intervention: Amantadine sulfate 6.3 ± 0.87 mg/kg/d for 8 weeks
Number of subjects: 17
Study: 22551422

Group type: EXPERIMENTAL
Intervention: IMRT (25 × 2 Gy) and carbon ion boost (8 × 3 GyE)
Number of subjects: 29
Study: 22554343

Group type: EXPERIMENTAL
Intervention: IRIS plus bevacizumab (S-1 40-60 mg twice daily on Days 1 to 14, irinotecan 100 mg/m² and bevacizumab 5 mg/kg on Days 1 and 15 of a 28-day cycle)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: IRIS plus bevacizumab
Number of subjects: 52
Study: 22554401

Group type: EXPERIMENTAL
Intervention: FAQLQ-PF (Parent's form)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: FAQLQ-CF (Children's form)
Number of subjects: 94
Study: 22554417

Group type: EXPERIMENTAL
Intervention: Cystic fibrosis (CF) genotype functional class with minimal CFTR function
Number of subjects: 889

Group type: COMPARATOR
Intervention: Newborn screening
Number of subjects: 889

Group type: COMPARATOR
Intervention: Modifiable risk factors (cigarette smoke, hot tub use, breastfeeding, daycare)
Number of subjects: 889
Study: 22555165

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir-based HAART
Number of subjects: 17
Study: 22555568

Group type: EXPERIMENTAL
Intervention: Foot-worn device (AposTherapy)
Number of subjects: 34
Study: 22555974

Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with nonmyeloablative chemotherapy and TBI
Number of subjects: 4

Group type: COMPARATOR
Intervention: Adoptive immunotherapy with nonmyeloablative chemotherapy
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: IL-2 administration
Number of subjects: 4
Study: 22555973

Group type: EXPERIMENTAL
Intervention: Intravenous carfilzomib 20 mg/m(2) for all treatment cycles (Cohort 1)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Intravenous carfilzomib 20 mg/m(2) for cycle 1 and then 27 mg/m(2) for all subsequent cycles (Cohort 2)
Number of subjects: 129
Study: 22556025

Group type: EXPERIMENTAL
Intervention: Chartis™ Pulmonary Assessment System
Number of subjects: 80
Study: 22556318

Group type: EXPERIMENTAL
Intervention: QuantiFERON TB Gold In-Tube assay (QFT-GIT) monthly for 1 year
Number of subjects: 49
Study: 22558076

Group type: EXPERIMENTAL
Intervention: SMN2 copy number, levels of full-length SMN2 transcripts, SMN protein levels in SMA subjects
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SMN expression measures (transcript and protein)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SMN2 copy number, levels of transcript and protein
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: SMN expression in blood
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Full-length SMN transcript abundance
Number of subjects: 108
Study: 22558101

Group type: EXPERIMENTAL
Intervention: DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2) administered intravenously every 3 weeks at escalating doses (0.01 to 0.09 mg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DOTAP:cholesterol nanoparticles encapsulating a TUSC2 expression plasmid (DOTAP:chol-TUSC2)
Number of subjects: 31
Study: 22558154

Group type: EXPERIMENTAL
Intervention: Candidate biomarkers (proteins and metabolites)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transcripts
Number of subjects: 108
Study: 22558168

Group type: EXPERIMENTAL
Intervention: Cluster-randomized studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-randomized crossover studies
Number of subjects: 0
Study: 22559192

Group type: EXPERIMENTAL
Intervention: Low-frequency deep TMS (1 Hz for 10 min) applied over the left temporoparietal cortex, 10 daily treatment sessions at 110% of the motor threshold.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment (placebo) according to patient randomization.
Number of subjects: 18
Study: 22560391

Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD)
Number of subjects: 698
Study: 22560524

Group type: EXPERIMENTAL
Intervention: Anthropometric measures (weight, hip circumference, waist circumference, waist-hip ratio, waist-height ratio, weight-height ratio, body adiposity index, body mass index)
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: Anthropometric variables
Number of subjects: 2037

Group type: EXPERIMENTAL
Intervention: Anthropometric measures
Number of subjects: 2037
Study: 22560543

Group type: EXPERIMENTAL
Intervention: High-dose thoracic radiation (61.2 Gy over 5 weeks, daily 1.8-Gy fractions on days 1-22, then twice-daily 1.8-Gy fractions on days 23-33) with concurrent chemotherapy (Cisplatin 60 mg/m² IV on day 1, Etoposide 120 mg/m² IV on days 1-3 and days 22-24).
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-dose thoracic radiation with concurrent chemotherapy.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation offered to patients who achieved complete response.
Number of subjects: 72
Study: 22562047

Group type: EXPERIMENTAL
Intervention: Patients with major depressive disorder (MDD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 46
Study: 22562290

Group type: EXPERIMENTAL
Intervention: TNF-α serum levels measured before, one and 6 days after PCI
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Infarct size quantified by late gadolinium enhancement cardiovascular magnetic resonance imaging (LGE-CMR) on day six
Number of subjects: 42
Study: 22562517

Group type: EXPERIMENTAL
Intervention: Subretinal visual implant
Number of subjects: 10
Study: 22563089

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2) infused weekly on days 56, 63, 70, and 77 after transplantation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 35
Study: 22563743

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study: 22564202

Group type: EXPERIMENTAL
Intervention: Usual care plus a 16-session GCBT-D intervention (n = 140)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care (n = 159)
Number of subjects: 299